The FDA approved Abilify for treating irritability in autistic children ages 6 to 17 years. Bristol-Myers Squibb said approval was based on data from two Phase III studies that showed Abilify, when compared with a placebo, significantly improved scores on the Irritability subscale of the Aberrant Behavior Checklist.

Related Summaries